Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva/GSK settle Relafen litigation

Executive Summary

All patent litigation between Teva and GSK regarding generics of Relafen (nabumetone) has been settled, Teva says April 30. Teva entered generic nabumetone market in August 2001 with 500 mg and 750 mg tablets following successful Boston federal court challenge of GSK patent (1"The Pink Sheet" Aug. 20, 2001, p. 14)...

You may also be interested in...



Teva Purinethol (correction)

Purinethol (6-mercaptopurine) is a Teva product; it was misidentified as a GlaxoSmithKline product in a recent story in "The Pink Sheet" (Oct. 30, p. 33). Teva received rights to Purinethol July 1 as part of its patent settlement with GSK regarding Relafen (nabumetone) generics (1"The Pink Sheet" May 5, 2003, In Brief)...

Teva Purinethol (correction)

In a story on Purinethol (6-mercaptopurine) labeling, "The Pink Sheet" referred to the leukemia drug as a GlaxoSmithKline product ("The Pink Sheet" July 21, 2003, p. 33). Teva received rights to Purinethol July 1 as part of its patent settlement with GSK regarding generics of Relafen (nabumetone) (1"The Pink Sheet" May 5, 2003, In Brief)...

Teva Launching Generic Relafen After Court Rules GSK Patent Invalid

Teva is "immediately" launching generic nabumetone following an Aug. 14 court decision upholding its patent challenge to GlaxoSmithKline's Relafen.

Related Content

UsernamePublicRestriction

Register

PS041749

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel